Background {#Sec1}
==========

Spontaneous bacterial peritonitis (SBP) is a well-recognized and prevalent complication seen in cirrhotic patients with ascites, occurring in 10--25% of these patients \[[@CR1]--[@CR4]\]. It leads to more severe liver function damage, multi-organ failure and sepsis, thus affecting the prognosis of such patients \[[@CR5]--[@CR7]\]. Once SBP is diagnosed, appropriate antibiotic treatment must be started as soon as possible, without prior knowledge of the causative organisms or their in vitro drug sensitivities \[[@CR1], [@CR2]\]. Because Gram-negative *Enterobacteriaceae* members are recognized as the most common causative organisms of SBP, third-generation cephalosporins (TGCs) have been recommended as the first-line therapies for this condition \[[@CR1], [@CR2], [@CR8]\]. However, as cirrhotic patients require frequent hospitalization, undergo numerous invasive procedures, and are subject to antibiotic prophylaxis, some studies have suggested that the bacterial spectrum and resistance profiles of the causative pathogens of SBP have changed and show huge regional variation \[[@CR4], [@CR9], [@CR10]\]. Thus, the latest guidelines from the European Association for the Study of Liver (EASL) recommend that for empirical treatment of SBP in cirrhotic patients with ascites, distinguishing nosocomial SBP from community-acquired SBP is necessary \[[@CR11]\]. Moreover, whether the infection site is community-acquired or nosocomically acquired will influence the clinical outcome for patients with SBP, but large differences exist in the data from different studies \[[@CR4], [@CR12], [@CR13]\].

This study aimed to determine whether differences exist between the clinical and microbiological characteristics of nosocomial and community-acquired SBP. We also explored the use of a comprehensive approach to determine the possible prognostic factors for hospital mortality in relation to SBP.

Methods {#Sec2}
=======

Patients and study design {#Sec3}
-------------------------

The medical records of 334 patients (\> 18 years) with culture-positive SBP and who were hospitalized at Beijing Youan Hospital, Capital Medical University (Beijing Institute of Hepatology) from January 2012 to December 2016 were reviewed. We only included one episode of SBP for each patient within the study period. Patients with a culture that was positive for highly suspicious skin contaminants, namely, *coagulase negative Staphylococci* (when the same strain was isolated twice or more from one patient and the treatment records were available, it was counted in this study), *Corynebacterium*, *Propionibacterium*, or *Bacillus* spp., and those with secondary peritonitis were excluded from our study. This study was carried out in accordance with the principles of the Declaration of Helsinki and was formally approved by the Institutional Medical Ethics Committee of Beijing Youan Hospital, Capital Medical University, China.

Definitions {#Sec4}
-----------

Culture-positive SBP was defined as a sample having a polymorphonuclear leukocyte count of ≥250 cells per mm^3^ in ascitic fluid and an ascitic fluid culture that was positive for a single organism. Community-acquired SBP was defined as an infection diagnosed within the first 48 h of admission to hospital, whereas a diagnosis made more than 48 h after hospitalization was defined as nosocomial SBP. Secondary peritonitis was considered in patients where the following applied: a polymicrobial infection, peritoneal dialysis, an indwelling abdominal catheter, and a recent history of abdominal surgery. The baseline data of patients with nosocomial SBP were assessed at the moment of SBP diagnosis. By reviewing the medical records and implementing a telephone follow-up survey, each patient was followed for 30 d after their diagnosis of SBP to determine the outcome.

Laboratory testing {#Sec5}
------------------

Bacterial identification and antibiotic susceptibility tests were performed according to the standard procedures established by the Clinical and Laboratory Standards Institute (CLSI). Cultivated microorganisms were identified using PHOENIX-100 (Becton Dickinson, Mountain View, CA, United States) instrumentation and matrix-assisted laser desorption/ionization-time of flight mass spectrometry (Bruker Daltonics, Germany). The antibiotic susceptibility testing was performed using PHOENIX-100 and confirmed by the Kirby-Bauer method on Müller-Hinton agar (Oxoid, Basingstoke, UK). The drug sensitivity test results were assessed according to the CLSI standards of 2012. *Staphylococcus aureus* ATCC25923, *Escherichia coli* ATCC25922, and *Pseudomonas aeruginosa* ATCC27853 were used as the quality control strains.

Statistical analysis {#Sec6}
--------------------

SPSS 17.0 (SPSS, Chicago, IL, USA) was used for all the statistical analyses. Comparisons of the categorical variables were performed using χ^2^, Fisher's exact test, or continuity correction, as appropriate. Continuous variables were compared using the Student's *t* test. To determine the risk factors associated with mortality, the proportional-hazards Cox regression model was used to control the effects of the confounding variables. Variables with *P \<* 0.05 in the univariate analyses were candidates for multivariate analysis. All *P* values were 2-tailed, and *P* values of *\<* 0.05 were considered to be statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

During the study period, 748 patients were diagnosed with SBP. From these patients, 334 (44.7%) who were diagnosed with culture-positive SBP were enrolled in this study, of which 270 were males and 64 were females. Their ages ranged from 18 to 87 years and the mean age was 55.5 ± 10.4 years. Hepatitis B virus (145 patients, 43.4%) was the most common cause of cirrhosis, followed by alcohol (123 patients, 36.8%), and hepatitis C virus (31 patients, 9.3%). The patients were divided into two groups according to the type of infection: the nosocomial SBP group (*n* = 155, 46.4%) and the community-acquired SBP group (*n* = 179, 53.6%). There were no statistically significant differences in age, sex, liver cirrhosis cause, Child-Pugh classification, hepatic encephalopathy, septic shock or gastrointestinal bleeding between the two groups. Concerning clinical signs, such as fever, abdominal pain, renal failure and hepatocellular carcinoma were statistically significantly more common among the patients with nosocomial infections. The clinical and demographic characteristics of the study population are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of patients with spontaneous bacterial peritonitisCharacteristicTotal\
(*n* = 334, %)Nosocomial SBP\
(*n* = 155, %)Community-acquired SBP\
(*n* = 179, %)*P* valueAge, mean years ± SD55.5 ± 10.456.3 ± 10.354.9 ± 10.40.222Sex, Male270 (80.8)127 (81.9)143 (79.9)0.635Main cause of liver cirrhosis (n, %)0.903 HBV infection145 (43.4)67 (43.2)78 (43.6)0.949 HCV infection31 (9.3)17 (11.0)14 (7.8)0.323 Alcohol use123 (36.8)55 (35.5)68 (38.0)0.636 Primary biliary cirrhosis15 (4.5)7 (4.5)8 (4.5)0.984 Other20 (6.0)9 (5.8)11 (6.1)0.896Child-Pugh classification0.453 Class B82 (24.6)41 (26.5)41 (22.9) Class C252 (75.4)114 (73.5)138 (77.1) MELD score ± SD16.9 ± 9.717.6 ± 10.016.0 ± 9.40.218Initial presenting symptoms Fever178 (53.3)107 (69.0)71 (39.7)\< 0.001 Vomiting/diarrhea57 (17.1)30 (19.4)27 (15.1)0.301 Abdominal pain153 (45.8)81 (52.3)72 (40.2)0.028 Hepatic encephalopathy69 (20.7)38 (24.5)31 (17.3)0.105 Gastrointestinal bleeding38 (11.4)18 (11.6)20 (11.2)0.900 Renal failure65 (19.5)40 (25.8)25 (14.0)0.006 Septic shock25 (7.5)13 (8.4)12 (6.7)0.560 Hepatocellular carcinoma93 (28.7)55 (35.5)38 (21.2)0.004

Microbiological characteristics {#Sec9}
-------------------------------

A total of 334 pathogens were isolated from the ascetic fluid samples from the patients with SBP. There were 178 (53.3%) strains of Gram-negative bacteria, 138 (41.3%) strains of Gram-positive bacteria, 14 strains of fungi and 4 anaerobic strains. *E. coli* was the major pathogen (81 isolates, 24.3%), followed by *Klebsiella pneumoniae* (40 isolates, 12.0%) and *Enterococcus faecium* (35 isolates, 10.5%). As shown in Table [2](#Tab2){ref-type="table"}, in the nosocomial group, the most common bacteria were *Enterococcus* (*n* = 43, 27.7%), followed by *E. coli* (*n* = 32, 20.6%), *K. pneumoniae* (*n* = 14, 9.0%), *coagulase-negative Staphylococci* (*n* = 12, 7.7%) and *S. aureus* (*n* = 9, 5.8%). Contrastingly, in the community-acquired group, the most common bacterial species were *E. coli* (*n* = 49, 27.4%) and *K. pneumoniae* (*n* = 26, 14.5%), followed by the *Streptococcus* genus (*n* = 23, 12.8%), *coagulase-negative Staphylococci* (*n* = 19, 10.6%) and the *Enterococcus* genus (*n* = 11, 6.1%). No statistically significant differences were found in the distribution of *E. coli*, *K. pneumoniae*, *coagulase-negative Staphylococcus*, and *S. aureus* between the two groups. However, there were more Gram-positive cocci in the nosocomial group (*n* = 73) than in the community-acquired group (*n* = 65, *P* \< 0.05). Statistically significant differences were also found in the distribution of *Enterococci* between the two groups (6.1% vs. 27.7%, *P* \< 0.001), and *Enterococci* were more commonly found in the nosocomial group.Table 2Bacteria distributions in nosocomial and community-acquired spontaneous bacterial peritonitisPathogenNo. (%) of patients*p* valueTotal\
(n = 334, %)Nosocomial SBP\
(n = 155, %)Community-acquired SBP (n = 179, %)Gram-negative bacteria178 (53.3)75 (48.4)103 (57.5)0.094*Escherichia coli*81 (24.3)32 (20.6)49 (27.4)0.152*Klebsiella pneumoniae*40 (12.0)14 (9.0)26 (14.5)0.123*Acinetobacter spp.*11 (3.3)6 (3.9)5 (2.8)0.582*Enterobacter cloacae*7 (2.1)3 (1.9)4 (2.2)0.849*Enterobacter species*19 (5.7)8 (5.2)11 (6.1)0.699*Pseudomonas aeruginosa*7 (2.1)3 (1.9)4 (2.2)0.849*Aeromonas species*4 (1.2)1 (0.6)3 (1.7)0.719*Sphingomonas paucimobilis*1 (0.3)1 (0.6)0 (0.0)0.464*Salmonella*1 (0.3)0 (0.0)1 (0.6)NS*Stenotrophomonas maltophilia*7 (2.1)7 (4.5)0 (0.0)0.004Gram-positive bacteria138 (41.3)73 (47.1)65 (36.3)0.046*Streptococcus pneumoniae*6 (1.8)1 (0.6)5 (2.8)0.289*Streptococcus (other than S. pneumoniae)*26 (7.8)8 (5.2)18 (10.1)0.096*Enterococcus faecalis*16 (4.8)14 (9.0)2 (1.1)0.002*Enterococcus faecium*35 (10.5)28 (18.1)7 (3.9)\< 0.001*Other Enterococcus*3 (0.9)1 (0.6)2 (1.1)NS*Staphylococcus aureus*16 (4.8)9 (5.8)7 (3.9)0.418*Coagulase-negative staphylococci*31 (9.3)12 (7.7)19 (10.6)0.376*Listeria monocytogenes*5 (1.5)0 (0.0)5 (2.8)0.064Fungi14 (4.2)6 (4.5)8 (3.9)0.786*Candida albicans*7 (2.1)3 (2.6)4 (1.7)*Candida glabrata*3 (0.9)1 (0.6)2 (1.1)*Candida tropicalis*2 (0.6)1 (0.6)1 (0.6)*Candida parapsilosis*1 (0.3)1 (0.6)0 (0.0)*Cryptococcus neoformans*1 (0.3)0 (0.0)1 (0.6)Anaerobe4 (1.2)1 (0.6)3 (1.7)0.627

The carbapenem antibiotics, amikacin and piperacillin/tazobactam, were the most consistently active in vitro drugs against *E. coli* and *K. pneumonia* in both the nosocomial and community-acquired infection groups (Table [3](#Tab3){ref-type="table"}). Piperacillin/tazobactam and levofloxacin were significantly more effective against community-acquired *E. coli* infections, whereas cefepime was significantly more effective against community-acquired *K. pneumonia* infections (all *P* \< 0.05). In addition, forty strains of extended-spectrum beta lactamase (ESBL)-producing *E. coli* and 6 strains of ESBL-producing *K. pneumonia* were detected, with detection rates of 49.4% (40/81) and 15.0% (6/40), respectively. The number of ESBL-producing *E. coli* was significantly higher for the nosocomial infections than for the community-acquired infections (*P* \< 0.001). However, no obvious differences were observed for the *K. pneumonia* infections.Table 3Comparison of the drug resistance of major gram-negative bacteria to commonly used antibacterial agents between nosocomial and community-acquired SBPAntibiotics*Escherichia coli* (*n* = 81)*Klebsiella pneumoniae* (*n* = 40)Nosocomial\
(n = 32)Community-acquired (n = 49)*p value*Nosocomial\
(n = 14)Community-acquired (n = 26)*p value*ESBL25 (78.1)15 (30.6)0.0004 (28.6)2 (7.7)0.194Ampicillin29 (90.6)43 (87.8)0.96814 (100)24 (92.3)0.533Piperacillin28 (87.5)37 (75.5)0.2996 (42.9)3 (11.5)0.062Amoxicillin-clavulanic acid12 (37.5)10 (20.4)0.0913 (21.4)1 (3.8)0.224Piperacillin/tazobactam4 (12.5)00.0222 (14.3)00.117Cefazolin26 (81.2)13 (26.5)0.0004 (28.6)4 (15.4)0.562Ceftazidime25 (78.1)13 (26.5)0.0004 (28.6)2 (7.7)0.194Cefotaxime27 (84.3)15 (30.6)0.0004 (28.6)2 (7.7)0.194Cefepime23 (71.9)11 (22.4)0.0004 (28.6)00.011Aztreonam18 (56.3)10 (20.4)0.0012 (14.3)1 (3.8)0.571Imipenem2 (6.3)00.1532 (14.3)00.117Meropenem1 (3.1)00.3951 (7.1)00.350Amikacin2 (6.3)00.1531 (7.1)00.350Levofloxacin23 (71.9)21 (42.9)0.013 (21.4)1 (3.8)0.224SMZ21 (65.6)30 (61.2)0.6883 (21.4)4 (15.4)0.965Gentamicin17 (53.1)25 (51.0)0.8532 (14.3)2 (7.7)0.912Tetracycline25 (78.1)39 (79.6)0.8744 (28.6)4 (15.4)0.562

Vancomycin, linezolid and teicoplanin showed good antibacterial activities against *S. aureus* and *Enterococci* (Table [4](#Tab4){ref-type="table"}). In addition, *S. aureus* displayed fairly high sensitivity (\> 85%) to nitrofurantoin, rifampin and sulfamethoxazole, but the community-acquired isolates of *S. aureus* were more sensitive to clindamycin than the nosocomial-acquired isolates (*P* = 0.044). *Enterococci* susceptibility to erythromycin and nitrofurantoin in the community-acquired group was stronger than in the nosocomial isolates (all *P* \< 0.05).Table 4Comparison of the drug resistance of major gram-positive bacteria to commonly used antibacterial agents between nosocomial and community-acquired SBPAntibiotics*Staphylococcus aureus* (*n* = 16)*Enterococcus* (*n* = 54)Nosocomial\
(n = 9)Community-acquired (n = 7)*p value*Nosocomial (n = 43)Community-acquired (n = 11)*p value*Penicillin8 (88.9)5 (71.4)0.55037 (86.0)8 (72.7)0.546Oxacillin6 (66.7)3 (42.9)0.615------Erythromycin8 (88.9)4 (57.1)0.26236 (83.7)6 (54.5)0.038Clindamycin7 (77.8)1 (14.3)0.041------Nitrofurantoin00NS25 (58.1)2 (18.2)0.043Rifampicin00NS37 (86.0)8 (72.7)0.546Tetracycline4 (44.4)2 (28.6)0.63324 (55.8)6 (54.5)0.940Ciprofloxacin5 (55.6)2 (28.6)0.35832 (74.4)8 (72.7)0.909SMZ1 (11.1)1 (14.3)NS------Linezolid00NS00NSVancomycin00NS8 (18.6)1 (9.1)0.762Teicoplanin00NS4 (9.3)00.571

Clinical outcome and predictors of mortality {#Sec10}
--------------------------------------------

The overall 30-day mortality rate for patients with SBP was 30.2% (101 of 334 cases). The mortality rate for nosocomial SBP was significantly higher than that for community-acquired SBP (36.8%, 57/155 cases vs. 24.6%, 44/179 cases; *P* = 0.016). The factors associated with the 30-day mortality rate are shown in Table [5](#Tab5){ref-type="table"}. The multivariate analysis revealed that the Child-Pugh classification (*p* = 0.007; HR, 2.167; 95% CI,1.236--3.798), nosocomial infection (*p* = 0.044; HR,1.514; 95% CI,1.012--2.267), hepatocellular carcinoma (*p* = 0.002; HR, 1.930; 95% CI, 1.284--2.901), renal failure (*p* \< 0.001; HR, 2.244; 95% CI, 1.440--3.496) and hepatic encephalopathy (*p* = 0.012; HR, 1.739; 95% CI, 1.129--2.677) were the independent predictors of 30-day mortality.Table 5Risk factors for 30-day mortality in patients with spontaneous bacterial peritonitisRisk factorSurvivors\
(*n =* 233)Nonsurvivors\
(*n* = 101)UnivariateMultivariate*P* value*p* valueHR95% CIAge, mean years \_ SD55.3 ± 10.756.1 ± 9.90.869------Male191790.401------Child-Pugh classification0.0070.0072.1671.236--3.798Class B6715Class C16686Hepatocellular carcinoma53400.0050.0021.9301.284--2.901Nosocomial infection98570.0050.0441.5141.012--2.267Resistance to third - generation cephalosporins77400.321------Gastrointestinal bleeding23150.105------Renal failure34310.001\< 0.0012.2441.440--3.496Septic shock14110.156------Hepatic encephalopathy3732\< 0.0010.0121.7391.129--2.677

Discussion {#Sec11}
==========

SBP is a serious complication and common cause of death in patients with liver cirrhosis, but early diagnosis and the timely application of antibiotic therapy can significantly decrease its mortality rate \[[@CR1], [@CR2]\]. However, the etiological patterns of peritonitis show huge regional differences \[[@CR4], [@CR9], [@CR10]\]. Thus, studying the epidemiology of SBP should be conducted at a local level with regard to the use of empirical therapy.

Gram-negative bacteria like *E. coli* and *K. pneumonia* are the most common causes of SBP \[[@CR1], [@CR2]\]. But several studies in recent years have shown that the major pathogens responsible for SBP have shifted from Gram-negative bacteria to Gram-positive cocci \[[@CR14]--[@CR17]\]. In contrast to these findings, and in agreement with the traditional model, our results show that Gram-negative bacteria (53.3%) remain the main etiological agents of SBP and that *E. coli* (24.3%) was its most common cause. Notably, Gram-negative bacteria were predominant in the community-acquired infections, whereas Gram-positive organisms were predominant in the nosocomial infections. This result is consistent with the data obtained from other investigations in mainland China \[[@CR18], [@CR19]\], indicating that no significant changes in the proportion of Gram-negative to Gram-positive infections occurred in the Chinese patients with SBP.

In recent years, some studies have reported on the emergence of resistance to TGCs in SBP \[[@CR20]--[@CR22]\]. Indeed, nosocomial infections are considered an independent predictor of resistance to these agents \[[@CR4], [@CR23]\]. In the present study, the resistant organisms cultured from ascites fluid mainly included *Enterococci*, ESBL-producing *Enterobacteriaceae* and some other naturally resistant bacteria (*Stenotrophomonas maltophilia* and *Listeria monocytogenes*). We found that ESBL production was higher in the samples from the nosocomial infection cases. Consequently, TGC resistance in the major Gram-negative bacteria was higher in the nosocomial group than in the community-acquired group. However, in a recent meta-analysis, Fiore et al found no significantly higher risk of TGC-resistant strains in nosocomial SBP compared with community-acquired SBP in China, although the total rate of TGC resistance was much higher than that seen in other countries \[[@CR24]\]. This discrepancy may be partly explained by differences in the study populations. Beijing Youan Hospital is one of the largest liver disease treatment centers in China, with patients coming from all over the country. Some of these patients might have been undergoing antibiotic therapy in other hospitals. In addition, the *E. coli* strains obtained from the patients with nosocomial SBP showed much higher resistance to piperacillin/tazobactam (12.2% vs. 0.0%) and levofloxacin (71.9% vs. 42.9%), than those from patients with community-acquired SBP. *K. pneumoniae*, however, was more resistant to cefepime when it was isolated from the nosocomial cases than from the community-acquired cases (28.8% vs. 0.0%). There was also a significant difference in the distribution of *Enterococci* between the two groups (nosocomial, 6.1% vs. community-acquired, 27.7%). *Enterococci* are resistant to a variety of antibacterial agents, including TGC, but are highly sensitive to vancomycin, linezolid and teicoplanin. This suggests that when choosing the treatment for empiric therapy of patients with SBP medics should consider both the acquisition site of infection (nosocomial or community-acquired infection) and the local epidemiological situation. The new guidelines from EASL also mention another epidemiological entity; specifically, health-care associated SBP, which requires the same therapeutic approach as that used for nosocomial SBP \[[@CR11]\]. However, as there is still controversy about its utility \[[@CR25]\], health-care associated SBP was not divided into a separate group in the present study.

Continual progress in health technology has markedly improved the prognosis for cirrhotic patients with SBP. But the one-year survival rate after recovery from the first episode of SBP is only 30--40% \[[@CR26], [@CR27]\]. A number of studies have sought to identify prognostic factors in patients with SBP \[[@CR4], [@CR10], [@CR12], [@CR23], [@CR28], [@CR29]\]. Consistent with other studies \[[@CR4], [@CR28], [@CR29]\], our results show that the Child-Pugh classification, concomitant hepatocellular carcinoma, renal failure presentation and hepatic encephalopathy are all significant risk factors for the 30-day mortality associated with SBP. As for nosocomial infections being a prognostic factor for SBP, some divergent opinions still exist. In our study, even after adjusting for the other prognostic factors associated with mortality, nosocomial SBP (*p* = 0.044; HR, 1.514; 95% CI, 1.012--2.267) was still identified as an independent risk factor for mortality. This view is consistent with the study findings of Cheong et al*,* \[[@CR4]\] but differs from other studies in Korea \[[@CR12], [@CR13]\], which have all highlighted that the acquisition site of infection does not affect the clinical outcomes for patients with SBP. Differences in the study populations and variable therapeutic regimens may play a part in this discrepancy. But researchers also think that the high mortality rate for patients with SBP reflects both the presence of infectious diseases and the underlying illness itself. In general, patients with nosocomial SBP have more severe underlying illnesses than those with community-acquired SBP \[[@CR14]\]; hence, it is not surprising that nosocomial SBP has a worse prognosis. Previous studies \[[@CR4], [@CR23], [@CR28], [@CR29]\] have also reported that resistance to TGC is an independent predictor of mortality in patients with SBP. However, the effects of such resistance could not be confirmed in our study. The difference between these other studies and our own may result from heterogeneity in the pathogens. Clearly, a bigger sample size will be needed in future research to verify this.

Our study has some limitations. First, the study comprised a single-center retrospective design and a relatively small sample size, and this may have compromised its statistical power. Second, the 2 groups are not completely comparable in their baseline characteristics (i.e., the higher prevalence of HCC in nosocomial infections reflect that these patients had a more advanced liver disease), to some extent, these selective bias could have influenced the higher mortality rate in the nosocomial SBP group. Third, only patients with SBP based on positive cultures were included in this study; we excluded patients with culture-negative neutrocytic ascites. Thus, selection bias may have occurred.

Conclusion {#Sec12}
==========

In conclusion, in the present study, Gram-negative bacteria remain the most prevalent cause of SBP, but compared with the community-acquired group, the proportion of *Enterococci* responsible for SBP was significantly higher in the nosocomial group. The resistance rate of the main pathogenic bacteria to TGC was very high, particularly in patients with nosocomial SBP. Thus, the choice of antibiotics used as empirical therapy in patients with SBP should consider both the acquisition site of infection and the local epidemiological situation. Of particular note, nosocomial acquisition was found to be significantly associated with higher mortality rates, along with Child-Pugh classification, concomitant hepatocellular carcinoma, renal failure, and hepatic encephalopathy.

SBP

:   Spontaneous bacterial peritonitis

ESBL

:   Extended-spectrum beta lactamase

TGC

:   Third-generation cephalosporins
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